HUSSMAN STRATEGIC ADVISORS, INC.
Position in PTGX — Protagonist Therapeutics, Inc
CIK 1179475
ELLICOTT CITY, MD
Position in PTGX
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$1,106,700
+$6,216 QoQ
Shares Held
10,500
-16.7% QoQ
Ownership
0.016%
of shares outstanding
% of Portfolio
0.24%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PTGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026HUSSMAN STRATEGIC ADVISORS, INC. holds $50,152,977 across 23 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
42,000 | $4,761,120 | |
| 2 | AUPH |
Aurinia Pharmaceuticals Inc.
|
210,000 | $3,563,700 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
42,000 | $3,287,340 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
5,250 | $3,273,585 | |
| 5 | INBX |
Inhibrx Biosciences, Inc.
|
31,500 | $2,984,625 | |
| 6 | TGTX |
Tg Therapeutics, Inc.
|
52,500 | $2,884,350 | |
| 7 | SRPT |
Sarepta Therapeutics, Inc.
|
147,000 | $2,641,590 | |
| 8 | PTCT |
Ptc Therapeutics, Inc.
|
31,500 | $2,569,455 |
All Filings in PTGX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,106,700 | 10,500 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $1,100,484 | 12,600 | Shares | Sole | 2026-02-02 | |
| 2025-09-30 | $1,395,030 | 21,000 | Shares | Sole | 2025-11-03 | |
| 2025-06-30 | $1,741,005 | 31,500 | Shares | Sole | 2025-08-05 | |
| 2025-03-31 | $2,538,900 | 52,500 | Shares | Sole | 2025-05-05 | |
| 2024-12-31 | $4,053,000 | 105,000 | Shares | Sole | 2025-02-03 | |
| No filing history on record for this holder in this stock. | ||||||